Weight Loss Drug Acomplia Rimonabant


by Lazyurl - Date: 2007-06-18 - Word Count: 249 Share This!

Acomplia (Rimonabant) is a pill to reduce obesity. Acomplia Rimonabant is an anti- obesity oral prescription drug with Rimonabant as its chief constituent. Rimonabant Acomplia is one of a first kind of therapeutic agents known as CB1. Rimonabant is sold in the UK and EU under brand name Acomplia and in USA under brand name Acomplia. Acomplia Rimonabant is manufactured by world famous french pharmaceuticals Sanofi-Aventis.
Rimonabant Acomplia Benefits
Besides, weight loss Acomplia Rimonabant is also beneficial for smoking cessation and cardio-vascular/ metabolic related risk factors related to obesity. Acomplia Rimonabant's 2yrs clinical trials have reflected promising signs of averting weight regain after preceding weight loss.
Rimonabant Acomplia Dosage
The usual prescribed dosage of Acomplia (Rimonabant) is 20mg. Do not overdose it. Strictly adhere to your doctor's prescription for a desirable weight loss.It is advisable to make your doctor well-informed regarding your medical history including any medication you may be engaged in. Pregnant women and nursing mothers should abstain from intake of Acomplia (Rimonabant).
Chantix / Champix Quit Smoking Drug
The most popular and effective treatment is the use of Chantix, the anti-smoking drug which was approved by the FDA on May 11, 2006. Chantix Champix is the only medicine, which lives upto its reputation and name. Due to its effectiveness doctors today are prescribing chantix to most of their patient who come for anti-smoking treatment. Only if they are allergic or face severe side effects only then they are referred another treatment. One doctor says out of the 22 patients he had prescribed

Related Tags: quit smoking, weight loss drug, buy acomplia, chantix, buy rimonabant, buy zimulti, champix

Your Article Search Directory : Find in Articles

© The article above is copyrighted by it's author. You're allowed to distribute this work according to the Creative Commons Attribution-NoDerivs license.
 

Recent articles in this category:



Most viewed articles in this category: